Quantitative Pharmacology and Translational Modeling

• 1813 · PDF A sensitive MSD-ECL platform for in vivo pharmacokinetic profiling of ADCs Carla N. Castro, Jonas Hummel, Philipp Metzger, Cynthia Obodozie, Holger Weber
• 1814 · PDF An integrated DMPK and bioanalytical platform for comprehensive characterization of antibody-drug conjugates (ADCs) Kefeng Gong, Xinhe Feng, Zhengyi Hua, Yanting Ma, Rui Wang, Xiaolong Tu, Luke Yu
• 1815 Nonclinical characterization of SBE303: A nectin-4 targeted antibody drug conjugate (ADC) with novel topoisomerase 1 inhibitor shows a favorable safety margin Ji Yeon Kim, Sungwoo Hyung, Hyun-Ji Choi, Songhyun Lim, Jae Hee Lee, Seokuee Kim, Donghyun Kim, So-Shin Ahn, Donghoon Shin
• 1816 · PDF ACSL4 mediated ferroptosis and its potential role in enhancing the efficacy of antibody-drug conjugates Shigehiro Koganemaru, Hirobumi Fuchigami, Hiroshi Tsugawa, Hiroko Shinohara, Yasutoshi Kuboki, Toshimitsu Uenaka, Toshihiko Doi, Masahiro Yasunaga
• 1818 · PDF Overcoming resistance with OBI-902: Preclinical evaluation of a next-generation TROP2 ADC Ren-Yu Hsu, Chi-Huan Lu, Chi-Sheng Shia, Jing-Rong Huang, Hsin-Shan Wu, Lu-Tzu Chen, Jhih-Jie Yang, Tzu-Min Yen, Jyy-Shiuan Tu, Yu-Hsuan Tsao, Ya-Chi Chen
• 1819 OBI-904, a glycan-based site-specific Nectin-4-targeted ADC, demonstrates potent and durable antitumor activity with an improved PK profile and overcoming EV-resistance in non-clinical studies Chi-Huan Lu, Ren-Yu Hsu, Jing-Jie Ciou, Tzu-Min Yen, Jyy-Shiuan Tu, Yu-Hsuan Tsao, Jing-Rong Huang, Ya-Chi Chen
• 1820 Pharmacokinetic-tumor growth inhibition modeling of raludotatug deruxtecan (R-DXd) to support phase 3 dose selection in platinum-resistant ovarian cancer (PROC) YoungJun Yoo, Kevin Koloskoff, Sandra Re, Izna Ali, Felipe K. Hurtado, Raouf El Cheikh
• 1821 Preclinical efficacy and safety of CS5006, a novel integrin beta4-targeting antibody-drug conjugate with a topoisomerase 1 inhibitor payload Chuan Wang, Xinling Zhang, Ning Zhang, Yamin Wang, Yongwang Li, Mengyao Zhu, Xuelian Liu, Yaxin Chen, Yuxin Qian, Yongli Yang, Jingyu Sun, Fei Ma, Jianxin Yang
• 1822 Preclinical efficacy and safety of CS5008, a novel SSTR2×DLL3 bispecific antibody-drug conjugate (ADC) with topoisomerase 1 inhibitor payload for small cell lung cancer and neuroendocrine tumors Chuan Wang, Yongwang Li, Ning Zhang, Yamin Wang, Xinling Zhang, Xuelian Liu, Yuxin Qian, Hui Dai, Xueqin Dai, Yaxin Chen, Zicong Zheng, Wenjing Xiang, Fei Ma, Jianxin Yang
• 1823 Preclinical efficacy and safety of CS5007, an EGFR×HER3 dual-targeting antibody-drug conjugate with a topoisomerase 1 inhibitor payload Chuan Wang, Yamin Wang, Ning Zhang, Xinling Zhang, Yongwang Li, Yuxin Qian, Yaxin Chen, Yongli Yang, Xuelian Liu, Mengyao Zhu, Hui Dai, Wenjing Xiang, Xueqin Dai, Fei Ma, Jianxin Yang
• 1824 · PDF ORM-1153: A Next-Generation CD123-Targeting Degrader Antibody Conjugate (DAC) Adam T. Boutin, Dong-Ki Choi, YeonHee Yang, Jessica Alves, MinSoo Kim, Da-Yeong Kim, Khuloud Takrouri, Qinsi Zheng, Nadia Cherkassky, Anna Skaletskaya, Teresa Mako, VineetKumar Patil, Hangyeol Jeong, Olaf Christensen, Maysoun Shomali, Sang Hyun Lee, James Palacino
• 1825 · PDF QSP modeling to inform dose and regimen selection for TAK-280: A bi-specific antibody Agnish Dey, Tao Long, Sabrina Collins, Dean Bottino, Jaydeep Srimani, John Gibbs
• 1826 Exposure-response analysis and quantitative systems pharmacology modeling for an optimal dose selection of surovatamig in patients with DLBCL Xu (Sue) Zhu, Damilola Olabode, Massimo Lai, Cesar Pichardo-Almarza, Meenu Pillai, Denise Brennan, David Sermer, Robin Lesley
• 1827 · PDF Combining PRC2 inhibitors with metronomic chemotherapy: A promising therapeutic strategy for diffuse large B-cell lymphoma Marta Banchi, Maryam Latarani, Paola Orlandi, Kayleigh Orchard, George Bryant, Francesco Crea, Guido Bocci
• 1828 Preclinical evaluation of selective and potent EP300 degraders demonstrates robust antitumor activity and favorable tolerability in hematologic malignancies Meiyun Lin, Wesley Austin, Qianhe Zhuo, Rieko Arimoto, Karolina Mizeracka, Abira Ramakrishnan, Kevin Wilson, Elizabeth Wittenborn, Laura La Bonte, Steven Bellon
• 1829 · PDF Treating breast cancer brain metastases in the leptomeninges through p-selectin targeted delivery of EZH2 PROTACs Raashed Raziuddin, Logan Hillger, Annie Ikemoto, Daniel Heller
• 1830 SP09253, an orally bioavailable, highly potent RAS(ON) molecular glue inhibitor demonstrates robust anti-tumor activity in KRAS-mutant tumors Zherong Zhang, Xiaoyu Di, Qiming Sun
• 1831 · PDF First-in-human clinical pharmacokinetic prediction of D3S-003, an orally bioavailable dual-state KRAS G12D inhibitor Shaonan Wang, Zhiqiang Zheng, Jing Zhang, Tienan Wang, Xin Xiong, Hui Wang, Zhijian Chen
• 1832 In silico calmodulin-PCAIs binding affinities versus in vitro anticancer cell viability: Strategies for the development of anti-pan-mutant KRAS agents Jahnissi Frimpomah Odoom, Kweku Ofosu-Asante, Joshua Kofi Ablordeppey, Desmond Kwakye, Amarender Burra, Nazarius Lamango
• 1833 Polyisoprenylated cysteinyl amide inhibitors suppress growth, induce cytoskeletal and transcriptomic remodeling in multiple KRAS -mutated lung cancer cells Desmond Kwakye, Chase Lilly, Kweku Ofosu-Asante, Jahnissi Frimpomah Odoom, Joshua Kofi Ablordeppey, Bianca Dal Bó, KARLA GONZALEZ, Chunli Yan, Matthew A. Gladstone, Kyle R. Phillips, Benjamin J. Ryder, Yong Huang, Ite A. Offringa, Nazarius Lamango
• 1834 · PDF A mathematical model for fitting adjusting azacytidine in AML or SMD patients Quentin Gerbault, Loic Osanno, Joseph Ciccolini, Laure Farnault, Geoffroy Venton, Raphaelle Fanciullino
• 1835 Evaluation of busulfan stability in infusion bags and biological matrix: Application to routine therapeutic drug monitoring with adaptive dosing in children Marielle Jehanno, Jasmine Bettayeb, Guillaume Sicard, Arthur Sterin, Joseph Ciccolini
• 1836 · PDF Nivolumab exposure and efficacy in metastatic melanoma patients: A real-world study Quentin Gerbault, Clara Boeri, Nausicaa Malissen, Caroline Gaudy, Joseph Ciccolini
• 1837 Targeting Hippo/YAP-TEAD increases the antitumor activity of darovasertib in uveal melanoma Rodolfo Daniel Cervantes-Villagrana, Elena Sofia Cardenas Alcoser, Kuniaki Sato, Simone Lubrano, Tomohiko Ishikawa, Andrew E. Aplin, J. Silvio Gutkind
• 1838 · PDF Optimal epigenetic therapies in triple-negative breast cancer Simone Bruno, Alexandra Indeglia, Sophia Lichterfeld, Karen M. Cichowski, Franziska Michor

在完整检索应用中浏览本分会场 →